In another promising study, the oncolytic HSV-TRAIL treatment of mice bearing a recurrent human GSC-derived tumor with TMZ-insensitivity inhibited tumor growth and extended animal survival (40% cure rate). The gene discussed is TNFSF10; the disease is neoplasm.